Breast Cancer Coverage from Every Angle


Advanced Breast Cancer: Is Abemaciclib Plus Endocrine Therapy of Benefit After Disease Progression?
ASCO 2024: Adjuvant Use of Avelumab in High Risk, Early-Stage Triple-Negative Breast Cancer
ASCO 2024: Phase II Survival Update of Palbociclib Plus Exemestane in Metastatic Breast Cancer
ASCO 2024: MUC1 Vaccine Plus Neoadjuvant Chemotherapy for Early-Stage Breast Cancer
ASCO 2024: Prognostic Role of ctDNA in the monarchE Breast Cancer Trial Population
ASCO 2024: Results From EV-202 of Enfortumab Vedotin in Breast Cancer Cohorts
ASCO 2024: Taxane-Free First-Line Regimen for Advanced HER2-Positive Breast Cancer
ASCO 2024: Is Adjuvant Endocrine Therapy Necessary for ER-Low Breast Cancer?
ASCO 2024: Novel Antibody-Drug Conjugate Under Study in Advanced Triple-Negative Breast Cancer
ASCO 2024: Taxane-Induced Peripheral Neuropathy in Black Women With Early-Stage Breast Cancer
ASCO 2024: DESTINY-Breast06 Update on T-DXd vs Chemotherapy in Metastatic Breast Cancer
Use of Everolimus in Advanced ER-Positive, HER2-Negative Breast Cancer: Molecular Features Influence Prognosis
ASCO 2024: Longest Reported Follow-up of Fertility and Pregnancy Among Survivors of Breast Cancer
Final ASCENT Trial Results: Sacituzumab Govitecan vs Chemotherapy in Triple-Negative Breast Cancer
Predicting a Woman’s Likelihood of Developing Breast Cancer: Focus on Polygenic Risk Scores
Final Recommendation Statement From USPSTF on Breast Cancer Screening
Clinical Effects of Breast-Conserving Therapy for BRCA-Mutated Disease
Coping With Fibrosis in the Years After Breast-Conserving Therapy
Early-Stage Triple-Negative Breast Cancer: Race and Pathologic Complete Response to Neoadjuvant Treatment
Technology-Based Program for Asian American Breast Cancer Survivors
Neoadjuvant Chemotherapy for Triple-Negative Breast Cancer: Does Presenting Stage Impact Overall Survival?
Breast Cancer Survivors and Risk for Primary Lung Cancer
Triple-Negative Breast Cancer: Aurora Kinase Inhibition and Neoadjuvant Chemotherapy
Predicting Responses to Chemotherapy-Free Neoadjuvant Therapy in Early-Stage Breast Cancer
AACR 2024: Immunostimulatory Properties of Low-Dose Chemotherapy in Triple-Negative Breast Cancer
AACR 2024: Response to Aromatase Inhibitors in ER-Positive Breast Cancer
AACR 2024: New-Generation PARP Inhibitor Under Study in HER2-Negative Breast Cancer
ASBrS 2024: How Will the Decline of Surgical Reimbursements Impact Breast Cancer Care?
AACR 2024: Novel Compounds May Target MIEN1 Pathway to Treat Breast Cancer
Retrospective Study Offers Insight Into Possible Overuse of Axillary Surgery
AACR 2024: DARPP-32 Protein and Progression of Breast Cancer
AACR 2024: Study Finds Potentially Targetable Mechanistic Pathway in Breast Cancer
AACR 2024: Classifying Patients With Triple-Negative Breast Cancer Based on Cellular Biomarkers
SSO 2024: De-escalation of Locoregional Therapy for Ductal Carcinoma in Situ
SSO 2024: Changes in Biomarker Profiles After Neoadjuvant Therapy for Breast Cancer
Can MRI Surveillance Reduce Breast Cancer Mortality in Women With BRCA1/2 Variations?
Identifying Residual Nodal Disease After Neoadjuvant Therapy for Breast Cancer: Focus on Clipped Axillary Node
EBCC 2024: Atezolizumab Plus Adjuvant Chemotherapy for Triple-Negative Breast Cancer
Cryoablation for Large Breast Tumors: An Alternative to Surgery for Some Patients?
SSO 2024: Nodal Isolated Tumor Cells and Axillary Dissection in Breast Cancer
Study Identifies Novel Therapeutic Targets for Males With Breast Cancer
Are Unmet Social Needs Linked to the Use of Breast Cancer Screening Mammography?
Australian Study Investigates Who May Safely Omit Postoperative Radiotherapy for Early Breast Cancer
Long-Term Update on Role of Adjuvant Abemaciclib Plus Endocrine Therapy for Early Breast Cancer
Not All Triple-Negative Breast Cancers Are Created Equal: Focus on Subtyping-Based Therapy
Novel Androgen Receptor Modulator, Enobosarm, Enters Breast Cancer Treatment Arena
Simulation Models Show Breast Cancer Screening and Treatment Advances Are Saving Lives
A Single-Port Robotic System for Nipple-Sparing Mastectomy
Final Overall Survival Analysis From PALOMA-2: Palbociclib Plus Letrozole in Advanced Breast Cancer
21-Gene Score in Ethnically Diverse, ER-Positive Breast Cancer: Implications for Young Non-Hispanic Black Women
Interrupting Breast Cancer Therapy to Attempt Pregnancy: Use of Assisted Reproductive Technologies
How Common Is Alpelisib-Induced Hyperglycemia in Metastatic Breast Cancer?
Potential Mechanism of Resistance in Breast Cancer Treatment: Focus on the PI3KA Pathway
Axillary Dissection of Residual Tumor Cells After Neoadjuvant Chemotherapy
MONARCH 3: Final Overall Survival Results With Abemaciclib-Based Therapy for Advanced Breast Cancer
Triple-Negative Breast Cancer: Are All PD-L1 Assays Created Equal?
Adding Ribociclib to Standard Hormone Therapy in Early-Stage Breast Cancer: NATALEE Update
Does Completion Axillary Lymph Node Dissection Impact Outcomes in Node-Positive Breast Cancer?
Adjuvant Atezolizumab Plus Standard Chemotherapy in Triple-Negative Breast Cancer
Regional Nodal Irradiation May Be Unnecessary for Some Patients With Breast Cancer Who Receive Neoadjuvant Chemotherapy
Can Younger Postmenopausal Patients Avoid Radiotherapy After Breast-Conserving Surgery?
SABCS 2023: Impact of Bilateral Mastectomy on Survival Among Patients With BRCA1-Mutated Breast Cancer
Long-Term Update on Neoadjuvant Pembrolizumab Plus Chemotherapy in Early-Stage Triple-Negative Breast Cancer

By continuing to browse this site you permit us and our partners to place identification cookies on your browser and agree to our use of cookies to identify you for marketing. Read our Privacy Policy to learn more.